Vicore Pharma Holding AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-424.45	-168.63	-310.94	-288.42	-296.48	-146.86
Depreciation & Amortization	0	2.24	3.42	3.61	3.6	3.54
Loss (Gain) From Sale of Assets	-	-	-	2	-	-
Asset Writedown & Restructuring Costs	-	-	62.55	-	-	-
Other Operating Activities	50.91	3.28	6.03	3.83	0.64	0.71
Change in Accounts Receivable	-3	-35.6	-4.28	-1.6	-0.34	-3.87
Change in Accounts Payable	32.41	33.77	-6.36	-19.34	27.41	26.55
Operating Cash Flow	-344.13	-164.95	-249.58	-299.92	-265.17	-119.94
Sale (Purchase) of Intangibles	-	-	-	-3	-	-3
Investment in Securities	-327.8	149.04	-144.46	77	-7	7
Investing Cash Flow	-329.21	149.04	-144.46	74	-7	4
Issuance of Common Stock	882.15	882.14	500.41	200	336	187.55
Other Financing Activities	-48.08	-48.08	-29.55	-12.96	-17.82	-10.58
Financing Cash Flow	834.07	834.06	470.86	187.04	318.18	176.97
Foreign Exchange Rate Adjustments	-27.3	4.23	-	1.48	-0.43	-
Net Cash Flow	133.43	822.38	76.82	-37.4	45.58	61.03
Free Cash Flow	-344.13	-164.95	-249.58	-299.92	-265.17	-119.94
Free Cash Flow Margin	-4048.09%	-150.85%	-	-	-	-
Free Cash Flow Per Share	-1.50	-1.21	-2.58	-4.15	-3.81	-2.21
Cash Interest Paid	0.06	0.01	0	0.01	0.01	0.01
Levered Free Cash Flow	-234.12	-111.57	-200.41	-195.17	-160.92	-71.86
Unlevered Free Cash Flow	-208.85	-111.56	-200.41	-195.16	-160.92	-71.86
Change in Working Capital	29.41	-1.84	-10.65	-20.94	27.07	22.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.